Moving away from PPARs - EGFR signaling and the anti-cancer effects of thiazolinedinediones.
Roman
Jesse
J
Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, Emory University School of Medicine, and Veterans Affairs Medical Center, Atlanta, Georgia 30322, USA. jroman@emory.edu
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002839:Chromans / Q000494:pharmacology; D042783:Endothelial Cells / Q000378:metabolism; D066246:ErbB Receptors / Q000378:metabolism*; D048049:Extracellular Signal-Regulated MAP Kinases / Q000378:metabolism; D051380:GRB2 Adaptor Protein / Q000378:metabolism; D047492:Peroxisome Proliferator-Activated Receptors / Q000172:deficiency / Q000378:metabolism*; D010766:Phosphorylation; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism; D015398:Signal Transduction; D013552:Swine; D045162:Thiazolidinediones / Q000494:pharmacology*; D000077288:Troglitazone
D000970:Antineoplastic Agents; D002839:Chromans; D051380:GRB2 Adaptor Protein; D047492:Peroxisome Proliferator-Activated Receptors; D045162:Thiazolidinediones; D066246:ErbB Receptors; D051057:Proto-Oncogene Proteins c-akt; D048049:Extracellular Signal-Regulated MAP Kinases; D000077288:Troglitazone